Cargando…
Pseudo-Mannosylated DC-SIGN Ligands as Immunomodulants
DC-SIGN, a C-type lectin mainly expressed by DCs, mediates antigen uptake and can induce specific immune responses, depending on the ligand involved. Owing to these properties, DC-SIGN is an attracting target for approaches aimed at tailoring the immune response towards specific immunologic outcomes...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5062166/ https://www.ncbi.nlm.nih.gov/pubmed/27734954 http://dx.doi.org/10.1038/srep35373 |
_version_ | 1782459724096077824 |
---|---|
author | Berzi, Angela Ordanini, Stefania Joosten, Ben Trabattoni, Daria Cambi, Alessandra Bernardi, Anna Clerici, Mario |
author_facet | Berzi, Angela Ordanini, Stefania Joosten, Ben Trabattoni, Daria Cambi, Alessandra Bernardi, Anna Clerici, Mario |
author_sort | Berzi, Angela |
collection | PubMed |
description | DC-SIGN, a C-type lectin mainly expressed by DCs, mediates antigen uptake and can induce specific immune responses, depending on the ligand involved. Owing to these properties, DC-SIGN is an attracting target for approaches aimed at tailoring the immune response towards specific immunologic outcomes. A multivalent DC-SIGN ligand (Polyman26), containing at its core a fluorescent “rod-like” spacer and able to inhibit DC-SIGN mediated HIV infection in nanomolar concentration, has been recently developed by our group. We investigated the internalization pattern and the ability of Polyman26 to elicit innate immune responses. Results obtained by confocal microscopy indicate that Polyman26 is internalized by DCs via receptor- mediated endocytosis and is then routed to endolysosomal compartments, thus being presented together with MHC class II molecules, with important implications for the development of vaccines. Moreover, Polyman26 up-regulated the production of β-chemokines and pro-inflammatory cytokines (including IL-1β, IL-6, IL-12, and TNFα) as well as the expression of TLR9 and CD40L. These results indicate that glycomimetic DC-SIGN ligands should be further investigated and suggest that these compounds could be used to differentially stimulate immune responses. |
format | Online Article Text |
id | pubmed-5062166 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-50621662016-10-24 Pseudo-Mannosylated DC-SIGN Ligands as Immunomodulants Berzi, Angela Ordanini, Stefania Joosten, Ben Trabattoni, Daria Cambi, Alessandra Bernardi, Anna Clerici, Mario Sci Rep Article DC-SIGN, a C-type lectin mainly expressed by DCs, mediates antigen uptake and can induce specific immune responses, depending on the ligand involved. Owing to these properties, DC-SIGN is an attracting target for approaches aimed at tailoring the immune response towards specific immunologic outcomes. A multivalent DC-SIGN ligand (Polyman26), containing at its core a fluorescent “rod-like” spacer and able to inhibit DC-SIGN mediated HIV infection in nanomolar concentration, has been recently developed by our group. We investigated the internalization pattern and the ability of Polyman26 to elicit innate immune responses. Results obtained by confocal microscopy indicate that Polyman26 is internalized by DCs via receptor- mediated endocytosis and is then routed to endolysosomal compartments, thus being presented together with MHC class II molecules, with important implications for the development of vaccines. Moreover, Polyman26 up-regulated the production of β-chemokines and pro-inflammatory cytokines (including IL-1β, IL-6, IL-12, and TNFα) as well as the expression of TLR9 and CD40L. These results indicate that glycomimetic DC-SIGN ligands should be further investigated and suggest that these compounds could be used to differentially stimulate immune responses. Nature Publishing Group 2016-10-13 /pmc/articles/PMC5062166/ /pubmed/27734954 http://dx.doi.org/10.1038/srep35373 Text en Copyright © 2016, The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Article Berzi, Angela Ordanini, Stefania Joosten, Ben Trabattoni, Daria Cambi, Alessandra Bernardi, Anna Clerici, Mario Pseudo-Mannosylated DC-SIGN Ligands as Immunomodulants |
title | Pseudo-Mannosylated DC-SIGN Ligands as Immunomodulants |
title_full | Pseudo-Mannosylated DC-SIGN Ligands as Immunomodulants |
title_fullStr | Pseudo-Mannosylated DC-SIGN Ligands as Immunomodulants |
title_full_unstemmed | Pseudo-Mannosylated DC-SIGN Ligands as Immunomodulants |
title_short | Pseudo-Mannosylated DC-SIGN Ligands as Immunomodulants |
title_sort | pseudo-mannosylated dc-sign ligands as immunomodulants |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5062166/ https://www.ncbi.nlm.nih.gov/pubmed/27734954 http://dx.doi.org/10.1038/srep35373 |
work_keys_str_mv | AT berziangela pseudomannosylateddcsignligandsasimmunomodulants AT ordaninistefania pseudomannosylateddcsignligandsasimmunomodulants AT joostenben pseudomannosylateddcsignligandsasimmunomodulants AT trabattonidaria pseudomannosylateddcsignligandsasimmunomodulants AT cambialessandra pseudomannosylateddcsignligandsasimmunomodulants AT bernardianna pseudomannosylateddcsignligandsasimmunomodulants AT clericimario pseudomannosylateddcsignligandsasimmunomodulants |